Starting from the wrong premise

Yes, not a day goes by without us looking at yet another way cool whiz bang toy. Even though the insulin pump market is dominated by Medtronic (NYSE: MDT) it seems as if everyone wants to play in this sandbox. Same can said for CGM, even though Dexcom (NASDAQ: DXCM) and Abbott (NYSE: ABT) are well ahead in this expanding market everyone wants to jump in. Heck even with BGM dying a slow and painful death money is still being thrown at ideas whose time has come and gone.

As we witnessed at JPM when Lilly (NYSE: LLY) talked about . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

This entry was posted in Email Alerts. Bookmark the permalink.